

Neil J Mchugh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8505311/publications.pdf>

Version: 2024-02-01

152
papers

6,310
citations

61984
43
h-index

74163
75
g-index

159
all docs

159
docs citations

159
times ranked

5660
citing authors

#	ARTICLE	IF	CITATIONS
1	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
2	Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. <i>Rheumatology</i> , 2009, 48, 607-612.	1.9	270
3	Autoantibodies in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 290-302.	8.0	248
4	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.9	240
5	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
6	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. <i>Journal of Autoimmunity</i> , 2019, 101, 48-55.	6.5	184
7	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.9	183
8	Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 701-707.	0.9	152
9	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	12.8	149
10	Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2014, 16, R138.	3.5	145
11	Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1358-1361.	0.9	141
12	Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. <i>Rheumatology</i> , 2014, 53, 2204-2208.	1.9	130
13	The CLASSification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study: Table 1.. <i>Journal of Rheumatology</i> , 2012, 39, 154-156.	2.0	125
14	Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. <i>Journal of Autoimmunity</i> , 2017, 84, 55-64.	6.5	121
15	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.9	107
16	Work disability in psoriatic arthritis: a systematic review. <i>Rheumatology</i> , 2012, 51, 275-283.	1.9	97
17	Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. <i>Arthritis Research and Therapy</i> , 2011, 13, 209.	3.5	93
18	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93

#	ARTICLE	IF	CITATIONS
19	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.9	87
20	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 996-1002.	0.9	81
21	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. <i>Rheumatology</i> , 2013, 52, 1754-1757.	1.9	79
22	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016, 2, e000282.	3.8	77
23	The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. <i>Rheumatology</i> , 2020, 59, 2109-2114.	1.9	77
24	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	3.9	76
25	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	1.9	73
26	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
27	Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. <i>Rheumatology</i> , 2017, 56, 2109-2113.	1.9	70
28	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	1.9	69
29	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.9	68
30	Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. <i>Rheumatology</i> , 2015, 54, 157-162.	1.9	66
31	The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. <i>Rheumatology</i> , 2019, 58, 650-655.	1.9	66
32	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography. <i>Arthritis and Rheumatology</i> , 2018, 70, 903-911.	5.6	65
33	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1882-1885.	0.9	64
34	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60
35	Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. <i>Rheumatology</i> , 2015, 54, 915-926.	1.9	60
36	Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. <i>Rheumatology</i> , 2015, 54, 2010-2014.	1.9	55

#	ARTICLE	IF	CITATIONS
37	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1373-1384.	3.4	54
38	Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies. <i>Frontiers in Immunology</i> , 2019, 10, 848.	4.8	54
39	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53
40	Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic Spondyloarthropathy. <i>Journal of Rheumatology</i> , 2015, 42, 21-30.	2.0	51
41	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1774-1779.	0.9	51
42	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
43	Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 277-280.	0.9	50
44	Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study. <i>Patient</i> , 2017, 10, 455-462.	2.7	48
45	Anti-HMGR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients. <i>Journal of Rheumatology</i> , 2017, 44, 488-492.	2.0	48
46	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2015, 10, e0143970.	2.5	45
47	Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. <i>Journal of Rheumatology</i> , 2015, 42, 1163-1168.	2.0	44
48	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
49	Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. <i>Lupus Science and Medicine</i> , 2017, 4, e000172.	2.7	42
50	Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. <i>Arthritis Research and Therapy</i> , 2017, 19, 210.	3.5	40
51	Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 712-717.	1.9	39
52	Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 343-347.	0.9	38
53	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	1.9	37
54	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.7	33

#	ARTICLE	IF	CITATIONS
55	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-“Tumor Necrosis Factor. Arthritis Care and Research, 2017, 69, 783-793.	3.4	32
56	Genetic association study of NF-“B genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology, 2012, 51, 794-799.	1.9	30
57	Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. Scientific Reports, 2017, 7, 8024.	3.3	30
58	Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. Journal of Rheumatology, 2016, 43, 1063-1067.	2.0	29
59	The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Research and Therapy, 2020, 22, 117.	3.5	27
60	Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology, 2021, 60, 3398-3403.	1.9	27
61	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. Journal of Investigative Dermatology, 2014, 134, 1459-1462.	0.7	26
62	Brief Report: Anti-“Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 2778-2783.	5.6	26
63	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-“treated rheumatoid arthritis patients. Rheumatology, 2019, 58, 2162-2169.	1.9	26
64	The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clinical Rheumatology, 2015, 34, 2089-2095.	2.2	24
65	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology, 2019, 58, 144-148.	1.9	24
66	Arthritis in Idiopathic Inflammatory Myopathy: Clinical Features and Autoantibody Associations. Journal of Rheumatology, 2014, 41, 1133-1139.	2.0	23
67	Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History. Journal of Rheumatology, 2015, 42, 1169-1176.	2.0	22
68	A rare coding allele inIFIH1is protective for psoriatic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1321-1324.	0.9	22
69	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. Rheumatology, 2019, 58, 468-475.	1.9	22
70	Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology, 2017, 56, kew433.	1.9	20
71	Implications of the diversity of class I HLA associations in psoriatic arthritis. Clinical Immunology, 2016, 172, 29-33.	3.2	19
72	Subjective and Objective Measures of Dryness Symptoms in Primary Sj“gren's Syndrome: Capturing the Discrepancy. Arthritis Care and Research, 2017, 69, 1714-1723.	3.4	18

#	ARTICLE	IF	CITATIONS
73	Autoantibodies in connective tissue disease. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101462.	3.3	17
74	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. Rheumatology International, 2017, 37, 623-631.	3.0	16
75	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology, 2020, 59, 1026-1030.	1.9	16
76	Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study. Journal of Rheumatology, 2019, 46, 1097-1102.	2.0	15
77	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. Arthritis and Rheumatology, 2022, 74, 1535-1543.	5.6	15
78	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. RMD Open, 2019, 5, e000885.	3.8	14
79	Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs. Journal of Rheumatology, 2020, 47, 701-707.	2.0	14
80	Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1206-1211.	2.0	13
81	Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis. Rheumatology, 2019, 58, 269-273.	1.9	13
82	Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. Rheumatology, 2021, 60, 2688-2696.	1.9	12
83	Diagnosis and initial management in psoriatic arthritis: a qualitative study with patients. Rheumatology Advances in Practice, 2019, 3, rkz022.	0.7	11
84	The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients. Rheumatology, 2020, 59, 1626-1631.	1.9	10
85	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. Scientific Reports, 2021, 11, 23335.	3.3	10
86	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. Rheumatology, 2015, 55, kev373.	1.9	9
87	Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. Annals of the Rheumatic Diseases, 2016, 75, 1417-1418.	0.9	9
88	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201674.	2.0	9
89	A Commercial Anti-TIF1 β ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing. Frontiers in Immunology, 2022, 13, 804037.	4.8	9
90	Verna Wright Lecture: Psoriatic Arthritis: The Need for Early Intervention. Journal of rheumatology Supplement, The, 2015, 93, 10-13.	2.2	8

#	ARTICLE	IF	CITATIONS
91	Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 831-835.	1.9	8
92	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020, 59, 1709-1714.	1.9	8
93	Myositis autoantibodies: recent perspectives. <i>Current Opinion in Rheumatology</i> , 2020, 32, 548-552.	4.3	8
94	Long-term effectiveness of tumour necrosis factor- α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky042.	0.7	7
95	Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. <i>Arthritis Research and Therapy</i> , 2018, 20, 176.	3.5	7
96	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.7	7
97	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021, 48, 48-57.	2.0	7
98	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. <i>Swiss Medical Weekly</i> , 2018, 148, w14588.	1.6	7
99	Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 880-884.	0.8	7
100	Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2015, 54, 1882-1889.	1.9	6
101	Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models. <i>Rheumatology</i> , 2021, 60, 1891-1901.	1.9	6
102	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266.	1.9	6
103	Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study. <i>Journal of Rheumatology</i> , 2016, 43, 367-370.	2.0	5
104	Reactivity in ELISA with DNA-loaded nucleosomes in patients with proliferative lupus nephritis. <i>Molecular Immunology</i> , 2015, 68, 20-24.	2.2	4
105	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016, 18, 156.	3.5	4
106	Exploring the illness representations of people with psoriatic arthritis: a secondary analysis of focus group data. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky023.	0.7	4
107	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 1588-1592.	1.9	4
108	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , 2021, 48, 1268-1271.	2.0	4

#	ARTICLE	IF	CITATIONS
109	Using Bayesian networks to identify musculoskeletal symptoms influencing the risk of developing psoriatic arthritis in people with psoriasis. <i>Rheumatology</i> , 2022, 61, 581-590.	1.9	4
110	Serological subsets of juvenile idiopathic inflammatory myopathies - an update. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 427-437.	3.0	3
111	Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibodyâ€“positive dermatomyositis: Reply. <i>Rheumatology</i> , 2019, 58, 2073-2074.	1.9	3
112	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201675.	2.0	3
113	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	3.4	3
114	Traditional Schemes for Treatment of Psoriatic Arthritis. <i>Journal of rheumatology Supplement</i> , The, 2009, 83, 49-51.	2.2	2
115	174â€“A Diagnostic and Treatment Challenge: The Prevalence and Clinical Associations of Anti-HMG-CoA Reductase Autoantibodies in a Large UK Juvenile-Onset Myositis Cohort. <i>Rheumatology</i> , 2016, 55, i132-i133.	1.9	2
116	Response to: â€“Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaâ€™ by Cavagna et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-212382.	0.9	2
117	O24â€“Low level detection of CTD-associated autoantibodies in patients with idiopathic pulmonary fibrosis confirms this as a robust phenotype when diagnosed on clinical grounds alone. <i>Rheumatology</i> , 2018, 57, .	1.9	2
118	O57â€“Autoantibody in Juvenile Dermatomyositis Reflects Disease Activity: Results of a Pilot Study. <i>Rheumatology</i> , 2014, 53, i54-i55.	1.9	1
119	O53â€“PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. <i>Rheumatology</i> , 2015, , .	1.9	1
120	17â€“Anti-synthetase autoantibody is seen in patients with overlap myositis in the UK cohort of patients with Jveunile Dermatomyositis. <i>Rheumatology</i> , 2017, 56, .	1.9	1
121	Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study. <i>BMC Rheumatology</i> , 2020, 4, 60.	1.6	1
122	Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity: reply. <i>Rheumatology</i> , 2020, 59, 2177-2178.	1.9	1
123	Role of ANA and Myositis Autoantibodies in Diagnosis. , 2020, , 167-174.		1
124	O44â€“An Integrative Analytical Approach to Subphenotyping of Juvenile Dermatomyositis. <i>Rheumatology</i> , 2015, , .	1.9	0
125	O48â€“A Negative Rheumatoid Factor Result in Primary Care Significantly Delays the Time to Diagnosis of Rheumatoid Arthritis: A Study using the Clinical Practice Research Datalink. <i>Rheumatology</i> , 0, , .	1.9	0
126	I112â€“New Drugs for Psoriatic Arthritis: The Rheumatologists Perspectiveâ€“To Include Apremilast, Ustekinumab and Secukinumab. <i>Rheumatology</i> , 0, , .	1.9	0

#	ARTICLE	IF	CITATIONS
127	175â€fMyositis-Specific Autoantibodies Rarely Coexist with Each Other: An Analysis of the Ukyonnet and Eumyonet Cohorts. Rheumatology, 0, , .	1.9	0
128	Biopsy pathology in a large cohort of juvenile dermatomyositis is heterogeneous and, for the most part, independent of autoantibody phenotype. Canadian Journal of Neurological Sciences, 2017, 44, S6-S6.	0.5	0
129	036â€fTHE ILLNESS PERCEPTIONS OF PEOPLE WITH PSORIATIC ARTHRITIS: A SECONDARY ANALYSIS OF FOCUS GROUP DATA. Rheumatology, 2017, 56, .	1.9	0
130	069â€fCONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. Rheumatology, 2017, 56, .	1.9	0
131	086â€fA longitudinal analysis of prevalence of sustained remission and low disease activity in rheumatoid arthritis patients treated with anti-tumour necrosis factor: an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2018, 57, .	1.9	0
132	A new era for collaboration?. Rheumatology, 2018, 57, 775-776.	1.9	0
133	i065â€fThe diagnostic utility of interstitial lung disease serology. Rheumatology, 2018, 57, .	1.9	0
134	187â€fImprovement of psoriatic nail disease in psoriatic arthritis patients treated with adalimumab: results of an observational cohort up to 36 months. Rheumatology, 2018, 57, .	1.9	0
135	117â€fAnti-TIF-1 antibody positivity is associated with a five-fold increase in cancer risk in the idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	1.9	0
136	242â€fBaseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology, 2019, 58, .	1.9	0
137	220â€fDiscrepancy between solid-phase immunoassays and immunoprecipitation in detecting anti-TIF1 gamma in patients with myositis. Rheumatology, 2019, 58, .	1.9	0
138	FRI0218â€f...IMMUNOPHENOTYPIC SUBGROUPS OF SLE DEFINED BY AUTOANTIBODIES, GENE EXPRESSION AND FLOW CYTOMETRIC ANALYSIS. , 2019, , .		0
139	294â€f...Immunophenotypic subgroups of SLE defined by autoantibodies, gene expression and flow cytometric analysis. , 2019, , .		0
140	P264â€fBurden of disease and relative impact of skin and joint disease on quality of life in PsA: analysis from a UK secondary care cohort. Rheumatology, 2020, 59, .	1.9	0
141	P265â€fBurden of psoriatic nail disease and response to biologic therapy in a PsA cohort. Rheumatology, 2020, 59, .	1.9	0
142	Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity: reply. Rheumatology, 2021, 60, e38-e38.	1.9	0
143	Risk of Osteoarthritis in an Incident Cohort of People With Psoriatic Arthritis: A Population-based Cohort Study. Journal of Rheumatology, 2021, 48, 841-846.	2.0	0
144	Preliminary Validation of the Severity of Nail Psoriasis Score (SNAPS) for the Assessment of Nail Psoriasis in Patients With Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 128-135.	0.7	0

#	ARTICLE	IF	CITATIONS
145	P163 Association between biomarkers and therapeutic pathway in patients with SLE. Rheumatology, 2021, 60, .	1.9	0
146	Newly Described Myositis Autoantibodies: HMCCR, NT5C1A, SAE, PUF60. , 2020, , 199-207.		0
147	Inflammatory myositis - Foray into the future. Indian Journal of Rheumatology, 2020, 15, 73.	0.4	0
148	P221 Autoantibodies are common in patients with idiopathic interstitial lung disease, suggesting a high prevalence of undiagnosed autoimmune connective tissue disease. Rheumatology, 2022, 61, .	1.9	0
149	OA12 Autoantibodies are common in patients labelled as "idiopathic" interstitial lung disease suggesting a high prevalence of undiagnosed autoimmune connective tissue disease. Rheumatology, 2022, 61, .	1.9	0
150	P222 Clinical features of extra-muscular disease in dermatomyositis and anti-synthetase syndrome patients with skin involvement classified by presence of disease-specific autoantibodies: results from the EuroMyositis registry. Rheumatology, 2022, 61, .	1.9	0
151	P224 Anti-PARP1 as a novel autoantibody in myositis. Rheumatology, 2022, 61, .	1.9	0
152	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0